Shares in GSK rose by as much as 3 per cent after it struck a deal with Boston Pharmaceuticals to acquire a liver disease drug in a deal that could hit $2 billion.
The drug is set to enter late-stage clinical trials and is being sold at an upfront price of $1.2 billion, while an additional $800 million could be paid in performance-related payments.
Stay up to date with breaking news in business, markets and current affairs, and our in-depth reporting and analysis on the stories that matter to you and your business.
Q: My spouse and I plan to divorce this year, and are attempting to keep things as...
The refurbished and extended Mercantile Hotel n Dublin city centre will reopen in...
US stocks declined and Treasury yields rose after Moody’s Ratings downgraded the...
Revenues continued to rise at Irish tech unicorn Intercom in the 12 months to the...
Colliers has been appointed to bring Sartini Court to the market, an exclusive PRS...
A new release of A2-rated homes at Fountain Field in Cloughabrody, Thomastown, Co...
For investors and developers looking to secure a foothold in Dublin city’s next...
